Chuck Norris' shocking 2017 lawsuit: Late actor sued 11 companies over wife's MRI 'poisoning' claim

Chuck Norris' death on 20 March 2026 has resurfaced his 2017 lawsuit, in which he and his wife, Gena O'Kelley, alleged that ...
Medscape

High-Dose Gadolinium May Be Linked to NSF/NFD in Patients with Renal Failure

June 9, 2006 — The U.S. Food and Drug Administration (FDA) has notified healthcare professionals regarding the potential risk for nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy ...
Business Insider

Guerbet concurs with the PRAC Recommendations on Gadolinium-based Contrast Agents and announces changes to the US labeling for its linear agent Optimark® (gadoversetamide ...

PRINCETON, N.J., March 31, 2017 /PRNewswire/ -- Guerbet LLC., subsidiary of Guerbet Group (FR0000032526 GBT), the global specialist in contrast products and solutions for medical imaging, takes note ...
Post-Bulletin

Contrast agents help create clear picture in certain types of MRI exams

DEAR MAYO CLINIC: I have had an acoustic neuroma for 10 years. When it was first diagnosed, I had fractionated stereotactic radiosurgery. Since then, I've had 18 MRIs with gadolinium injections. Have ...
KXAN

Bracco Announces FDA Approval of Gadopiclenol Injection, a New Macrocyclic High-Relaxivity Gadolinium-Based Contrast Agent which will be commercialized as VUEWAY ...

VUEWAY injection is highly stable and shows the highest relaxivity among gadolinium-based contrast agents available for clinical use i VUEWAY injection is approved for use in adult and pediatric ...
Monthly Prescribing Reference

Gadopiclenol, a New Macrocyclic Gadolinium-Based Contrast Agent, Gets FDA Approval

Gadopiclenol carries a Boxed Warning associated with an increased risk of nephrogenic systemic fibrosis among patients with impaired elimination of the drugs. The approval of gadopiclenol was based on ...
Morningstar

FDA Approves VUEWAY® (gadopiclenol) Solution for Injection, Intravenous Use, for Use in Neonates and Infants

Approval expands low-dose MRI contrast options for the youngest patients and reflects a positive benefit–risk profile of VUEWAY® injection from birth through adulthood PRINCETON, N.J., Feb. 23, 2026 ...